Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Oral fluconazole use in first trimester ups risks of musculoskeletal malformations

Stephen Padilla
27 May 2020
Useful guidelines to enhance client’s discharge planning

Use of oral fluconazole in the first trimester does not lead to oral clefts or conotruncal malformations but is associated with musculoskeletal malformations, a study has shown.

“Our study confirmed an increase in the risk of musculoskeletal malformations if fluconazole is used during the first trimester, and refuted large increased risks of conotruncal malformations, oral clefts, and other specific types of malformations,” the researchers said.

This population-based cohort study analysed a cohort of pregnancies publicly insured in the US, with data from the nationwide Medicaid Analytic eXtract 2000–2014. Use of fluconazole and topical azoles was established by requiring one or more prescriptions during the first trimester of pregnancy. The researchers then examined the risk of musculoskeletal malformations, conotruncal malformations, and oral clefts associated with oral fluconazole exposure, diagnosed during the first 90 days after delivery.

Of the 1,969,954 pregnancies identified, 37,650 (1.9 percent) were exposed to oral fluconazole and 82,090 (4.2 percent) to topical azoles during the first trimester. The risk of musculoskeletal malformations was 52.1 (95 percent confident interval [CI], 44.8–59.3) per 10,000 pregnancies exposed to fluconazole compared with 37.3 (95 percent CI, 33.1–41.4) per 10,000 pregnancies exposed to topical azoles. [BMJ 2020;369:m1494]

For conotruncal malformations, the risks were 9.6 (95 percent CI, 6.4–12.7) per 10,000 pregnancies exposed to fluconazole compared with 8.3 (95 percent CI, 6.3–10.3) per 10,000 pregnancies exposed to topical azoles. Risks for oral clefts were 9.3 (95 percent CI, 6.2–12.4) vs 10.6 (95 percent CI, 8.4–12.8) per 10,000 pregnancies, respectively.

The adjusted relative risk following fine stratification of the propensity scores was 1.30 (95 percent CI, 1.09–1.56) for musculoskeletal malformations, 1.04 (95 percent CI, 0.70–1.55) for conotruncal malformations, and 0.91 (95 percent CI, 0.61–1.35) for oral clefts overall.

The corresponding adjusted relative risks for musculoskeletal malformations, conotruncal malformations, and oral clefts based on cumulative doses of fluconazole were 1.29 (95 percent CI, 1.05–1.58), 1.12 (95 percent CI, 0.71–1.77), and 0.88 (95 percent CI, 0.55–1.40) for  fluconazole 150 mg; 1.24 (95 percent CI, 0.93–1.66), 0.61 (95 percent CI, 0.26–1.39), and 1.08 (95 percent CI, 0.58–2.04) for fluconazole >150–450 mg; and 1.98 (95 percent CI, 1.23–3.17), 2.30 (95 percent CI, 0.93–5.65), and 0.94 (95 percent CI, 0.23–3.82) for fluconazole >450 mg.

“The increased risk of musculoskeletal malformations … associated with exposure to fluconazole at common therapeutic doses during the first trimester aligns with the patterns of malformations reported in previous case reports at high doses,” the researchers said. [Pediatr Infect Dis J 1992;11:1062-1064; Clin Infect Dis 1996;22:336-240; Am J Med Genet 1997;72:253-256]

“Oral fluconazole during the first trimester, especially prolonged treatment at higher than commonly used doses, should be prescribed with caution, and topical azoles should be considered as an alternative treatment,” they noted.

A first-line treatment for vulvovaginal candidiasis, oral fluconazole is commonly used in women of reproductive age, leading to prenatal exposure. [Curr Infect Dis Rep 2015;17:462; Clin Infect Dis 2016;62:e1-50; Can Fam Physician 2009;55:255-256]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.